Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cellectis Announces Preliminary Clinical Data For UCART22 In ALL And UCART123 In AML

UCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient
byBenzinga Newsdesk
December 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • UCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion
  • UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a durable minimal residual disease (MRD)-negative complete response that continues beyond 12 months
  • BALLI-01 study (evaluating UCART22) now enrolling patients with product candidate manufactured in-house at DL2
  • AMELI-01 study (evaluating UCART123) now enrolling patients in a two-dose regimen arm at DL2

 

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Altamira Therapeutics’ Peptide-Based Delivery Platform Shown To Enhance Potency Of Commonly Used Gene Delivery Method Published In The Journal Of Integrative Medicine Titled, “Melittin Analog P5RHH Enhances Recombinant Adeno-Associated Virus Transducti…

By Benzinga Newsdesk
February 7, 9:48 AM
  Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating Altamira's peptide-based delivery technology     

CYTO

Read More

Intellia Therapeutics Highlights Its 3-Year Strategic Priorities And Anticipated 2024 Key Milestones; Ended 2023 In A Strong Financial Position With Approximately $1B In Cash; Cash Runway Extended Into Mid-2026

By Benzinga Newsdesk
January 4, 5:02 PM
Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of patient enrollment in the pivotal study of NTLA-2001, clinical validation of modular in vivo gene insertion

NTLA